Boston Scientific device outperforms warfarin in atrial fibrillation study

05/10/2013 | MassDevice.com (Boston)

Boston Scientific's Watchman device proved more effective and safer in treating patients with atrial fibrillation than the anti-coagulant drug warfarin, according to a 707-participant study. The study showed Watchman was superior to warfarin "for the combined endpoint of all stroke, cardiovascular or unexplained death and systemic embolism," the company said in a release.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ